Search

Your search keyword '"Jewett M"' showing total 516 results
Start Over Author "Jewett M"
516 results on '"Jewett M"'

2. Evaluation of the long term recurrence risk, metastatic potential and length of cystoscopic surveillance of low-grade non-muscle invasive bladder cancer

Author

Chan, A., primary, Lajkosz, K., additional, Villegas, E., additional, Vitug, C., additional, Din, S., additional, Kuk, C., additional, Gao, B., additional, Hemminiki, O., additional, Kot, D., additional, Misurka, J., additional, Black, P., additional, Jewett, M., additional, Soloway, M.S., additional, Roupret, M., additional, Comperat, E., additional, Shen, J., additional, Sweet, J., additional, Seisen, T., additional, Fleshner, N.E., additional, Wrana, J., additional, Van Der Kwast, T.H., additional, Kulkarni, G.S., additional, and Zlotta, A.R., additional

Published
2024
Full Text
View/download PDF

8. Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial

Author

Abu-Ghanem, Y., Thienen, J.V. van, Blank, C., Aarts, M.J., Jewett, M., Jong, I.J. de, Lattouf, J.B., Melick, H.H.E. van, Wood, L., Mulders, P.F.A., Rottey, S., Wagstaff, J., Zondervan, P., Powles, T., Neven, A., Collette, L., Tombal, B., Haanen, J., Bex, A., Abu-Ghanem, Y., Thienen, J.V. van, Blank, C., Aarts, M.J., Jewett, M., Jong, I.J. de, Lattouf, J.B., Melick, H.H.E. van, Wood, L., Mulders, P.F.A., Rottey, S., Wagstaff, J., Zondervan, P., Powles, T., Neven, A., Collette, L., Tombal, B., Haanen, J., and Bex, A.

Abstract

Item does not contain fulltext, OBJECTIVE: To analyse if exposure to sunitinib in the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial, which investigated opposite sequences of cytoreductive nephrectomy (CN) and systemic therapy, is associated with the overall survival (OS) benefit observed in the deferred CN arm. PATIENTS AND METHODS: A post hoc analysis of SURTIME trial data. Variables analysed included number of patients receiving sunitinib, time from randomisation to start sunitinib, overall response rate by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, and duration of drug exposure and dose in the intention-to-treat population of the immediate and deferred arm. Descriptive methods and 95% confidence-intervals (CI) were used. RESULTS: In the deferred arm, 97.7% (95% CI 89.3-99.6%; n = 48) received sunitinib vs 80% (95% CI 66.9-88.7%, n = 40) in the immediate arm. Following immediate CN, 19.6% progressed 4 weeks after CN and the median time to start sunitinib was 39.5 vs 4.5 days in the deferred arm. At week 16, 46.0% had progressed at metastatic sites in the immediate CN arm vs 32.7% in the deferred arm. Sunitinib dose reductions, escalations and interruptions were not statistically significantly different between arms. Among patients who received sunitinib in the immediate or deferred arm the median total sunitinib treatment duration was 172.5 vs 248 days. Reduction of target lesions was more profound in the deferred arm. CONCLUSIONS: In comparison to the deferred CN approach, immediate CN impairs administration, onset, and duration of sunitinib. Starting with systemic therapy leads to early and more profound disease control and identification of progression prior to planned CN, which may have contributed to the observed OS benefit.

Published
2022

9. Patient-centered care can be improved by joint meetings between cancer patient group leaders and health care providers

Author

Herrera-Caceres, J. O., Ajaj, R., Leao, R., Barello, Serena, Rodriguez-Covarrubias, F., Zequi, S. C., Maskens, D., Giles, R. H., Lavallee, L. T., Jewett, M. A. S., Barello S. (ORCID:0000-0002-8514-2563), Herrera-Caceres, J. O., Ajaj, R., Leao, R., Barello, Serena, Rodriguez-Covarrubias, F., Zequi, S. C., Maskens, D., Giles, R. H., Lavallee, L. T., Jewett, M. A. S., and Barello S. (ORCID:0000-0002-8514-2563)

Abstract

N/A

Published
2022

12. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer

Author

Ribnikar, D, Stukalin, I, Bedard, PL, Hamilton, RJ, Jewett, M, Warde, P, Chung, P, Anson-Cartwright, L, Templeton, AJ, Amir, E, Hansen, AR, Heng, DYC, Lewin, J, Ribnikar, D, Stukalin, I, Bedard, PL, Hamilton, RJ, Jewett, M, Warde, P, Chung, P, Anson-Cartwright, L, Templeton, AJ, Amir, E, Hansen, AR, Heng, DYC, and Lewin, J

Abstract

We investigated the prognostic utility of pre-chemotherapy neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors (GCTs) undergoing first-line chemotherapy. We utilized two institutional databases to analyze the pretreatment-derived NLR (dNLR). Predictive accuracy was evaluated using the Cox proportional hazard model adjusted for the international germ cell cancer collaborative group (IGCCCG) risk classification. Discriminatory accuracy was evaluated by determining the area under the receiver operating characteristic curve (AUROC). In total, 569 of 690 patients had available dNLR (IGCCCG: good, 64%; intermediate, 21%; poor, 16%). The 5-year and 10-year overall survivals (OSs) for good, intermediate, and poor risk groups were 96.2%, 92.8%, and 62.7% and 93.9%, 90.3%, and 62.7%, respectively. A dNLR of 2 provided the best discriminatory accuracy with an AUROC of 0.58 (95% CI: 0.52-0.65, p = 0.01) for progression-free survival (PFS), whereas for OS, a dNLR of 3 provided the best discriminatory accuracy with an AUROC of 0.62 (95% CI: 0.53-0.70, p < 0.01). A dNLR > 2 was associated with a hazard ratio (HR) of 1.99 (95% CI: 1.27-3.12, p < 0.01) for PFS, which lost its effect after adjustment for IGCCCG (HR: 1.44, 95% CI: 0.90-2.30, p = 0.13). For OS, a dNLR >3 was associated with an HR of 3.00 (95% CI: 1.79-5.01, p < 0.01), but lost its effect after adjustment for IGCCCG. Systemic inflammation plays a role in metastatic GCT, but its prognostic utility beyond established algorithms is limited. The general prognostic value of NLR can be seen across a number of tumors, although the consistency and magnitude of the effect differ according to cancer type, disease stage, and treatment received. We identified that an elevated NLR was associated with an adverse PFS and OS, but not independent of the IGCCCG risk classification. dNLRs >2 and >3 were associated with an adverse PFS and OS, respectively, in patients with metastatic GCT receiving first-line c

Published
2021

18. Abstracts

Author

Kavanagh, Brian P., Ngo, Cuong, Raymer, Karen, Yang, Homer, Alhashemi, Jamal A., Lui, Anne C. P., Reid, Dennis, Cicutti, Nicholas, Krepski, Barbra, Wood, Gordon, Heyland, Daren K., Badner, Neal H., Murkin, John M., Mohr, Jim, McKenzie, F. Neil, van der Starre, Peter J. A., van Rooyen-Butijn, W. T., Wilson-Yang, Kristine, Teoh, Kevin, Lee, R. M. K. W., Hossain, Imtiaz, Cheng, Davy, Karski, Jacek, Asokumar, Buvanendran, Sandier, Alan, St-Amand, Marc A., Murkin, John M., Menkis, Alan H., Downey, Donal B., Nantau, William, Adams, Sandy, Dowd, Noreen, Cheng, Davy, Wong, David, Carroll-Munro, Jo, Trachuk, Clare, Cregg, N., Cheng, D. C. H., Williams, W. G., Karski, J. M., Siu, S., Webb, G., Cheng, Davy C. H., Wong, David T., Kustra, Rafal, Karski, Jacek, Tibshirani, Robert J., Côté, Dany L., Lacey, David E., LeDez, Kenneth M., Smith, Julia A., Crosby, Edward T., Orkin, Fredrick K., Fisher, A., Volgyesi, G., Silverman, J., Edelstein, S., Rucker, J., Sommer, L., Dunington, S., Roy, L., Crochetière, C., Arsenault, M. -Y., Villeneuve, E., Lortie, L., Grange, Caroline S., Douglas, M. Joanne, Adams, Timothy J., Merrick, Pamela M., Lucas, S. Brian, Morgan, Pamela J., Halpern, Stephen, Lo, Jason, Giesinger, Carolyn L., Halpern, Stephen H., Breen, Terrance W., Vishnubala, Srigowri, Shetty, Geeta R., De Kock, M., Lagmiche, A., Scholtes, J. L., Grodecki, Wlodzimierz, Duffy, Peter J., Hull, Kathryn A., Hawboldt, Geoffrey S., Clark, Alexander J., Smith, J. Bruce, Norman, Richard W., Beattie, W. Scott, Sandier, A., Jewett, M., Valiquette, L., Katz, J., Fradet, Y., Redelmeier, D., Sampson, H., Cole, Jeff, Chedore, Todd, Snedden, Walter, Green, Robert G., Sosis, Mitchel B., Robles, Philip I., Lazar, Edward R., Jolly, Donald T., Tarn, Yun K., Tawfik, Soheir R., Clanachan, Alexander S., Milne, Avaleigh, Beamish, Travis, Cuillerier, D. J., Sharpe, M. D., Lee, J. K., Basta, M., Krahn, A. D., Klein, G. J., Yee, R., Vakharia, Narendra, Francis, Heather, Scheepers, Louis, Vaghadia, Himat, Carrier, Joanne, Martin, René, Pirlet, Marline, Claprood, Yves, Tétrault, Jean-Pierre, Wong, T. D., Ryner, L., Kozlowski, P., Scarth, G., Warrian, R. K., Lefevre, G., Thiessen, D., Girling, L., Doiron, L., McCudden, C., Saunders, J., Mutch, W. A. C., Duffy, Peter J., Langevin, Stéphan, Lessard, Martin R., Trépanier, Claude A., Hare, Gregory M. T., Ngan, Johnson C. S., Viskari, Dan, Berrill, A., Jodoin, Christian, Couture, Jacques, Bellemare, François, Farmer, Stephen, Muir, Holly, Money, Phyllis, Milne, Brian, Parlow, Joel, Raymond, Jennifer, Williams, Julie M., Craen, Rosemary A., Novick, Teresa, Komar, Wendy, Frenette, Luc, Cox, Jerry, Lockhart, B., McArdle, P., Eckhoff, D., Bynon, S., Dobkowski, Wojciech B., Grant, David R., Wall, William J., Chedrawy, Edgar G., Hall, Richard I., Nedelcu, Vivian, Parlow, Joel, Viale, Jean-Paul, Bégou, Gérard, Sagnard, Pierre, Hughson, Richard, Quintin, Luc, Troncy, Éric, Collet, Jean-Paul, Shapiro, Stan, Guimond, Jean-Gilles, Blair, Louis, Ducruet, Thiérry, Francœur, Martin, Charbonneau, Marc, Blaise, Gilbert, Snedden, W., Bernadska, E., Manson, H. I., Kutt, Juditli L., Mezon, Beruie Y., Nishida, Osamu, Arellano, Ramiro, Boylen, Patty, DeMajo, Wilfred, Archer, David P., Roth, Sheldon H., Raman, Sitaram, Manninen, Pirjo, Boyle, Kevin, Cenic, Aleksa, Lee, Ting-Yim, Gelb, Adrian W., Reinders, F. X., Brown, J. I. M., Baker, A. J., Moulton, R. J., Schlichtert, L., Schwarz, Stephan K. W., Puil, Ernest, Finegan, Barry A., Finucane, Brendan T., Kurrek, Matt M., Devitt, J. Hugh, Morgan, Pamela J., Cleave-Hogg, Doreen, Bradley, John, Byrick, Robert, Spadafora, Salvatore M., Fuller, John G., Gelula, Mark H., Mayson, Kelly, Forster, Bruce, Byrick, R. J., McKnight, D. J., Kurrek, M., Kolton, M., Cleave-Hogg, D., Haughton, J., Halpern, S., Kronberg, J., Shysh, Sandy, Eagle, Chris, Dagnone, A. Joel, Parlow, Joel L., Blaise, G., Yang, F., Nguyen, H., Troncy, E., Czaika, G., Wachowski, Ireneusz, Basta, M., Krahn, A. D., Yee, R., Deladrière, Hervé, Cambier, Chantal, Pendeville, Philippe, Hung, O. R., Coonan, E., Whynot, S. C., Mezei, M., Coonan, E., Whynot, S. C., Ho, Anthony M. -H., Luchsinger, Ingrid S., Ling, Elizabeth, Mashava, Doreen, Chinyanga, Herbert M., Cohen, Marsha M., Shaw, Melissa, Robblee J. A., Labow R. S., Rubens F. D., Diemunsch, A. M., Gervais, R., Rose, D. K., Cohen, M. M., O’Brien-Pallas, L., Copplestone, C., Rose, D. K., Karkouti, K., Sykora, K., Cheung, Shirley L. W., Booker, Peter D., Franks, Roger, Pozzi, Marco, Guard, Beverley, Sikich, Nancy, Lerman, Jerrold, Levine, Mark, Swan, Hilton, Cox, Peter, Montgomery, Carolyne, Dunn, Gillian, Bourne, Russell, Kinahan, Anna, McCormack, James, Dunn, Gillian S., Reimer, Eleanor J., Sanderson, Peter, Sanderson, Peter M., Montgomery, Carolyne J., Betts, Terri A., Orlay, Guy R., Wong, David H., Cohen, Marsha, Al-Kaisy, A. A., Chan, V., Peng, P., Perlas, A., Miniad, A., Cushing, Edward V., Mills, Keith R., El-Beheiry, Hossam, Jahromi, Shokrollah S., Weaver, John, Morris, Mary, Carien, Peter L., Cowan, Robert McTaggart, Manninen, Pirjo, Richards, Jonathan, Robblee, J. A., Labow, R. S., Rubens, F. D., Menkis, Alan H., Adams, Sandy, Henderson, Blair T., Hudson, Robert J., Thomson, Ian R., Moon, Michael, Peterson, Mark D., Rosenbloom, Morley, Davison, Patrick J., Ali, Mohamed, Ali, Naheed S., Searle, Norman R., Thomson, Ian, Roy, Micheline, Gagnon, Line, Lye, A., Walsh, F., Middleton, W., Wong, D., Langer, A., Errett, L., Mazer, C. D., Karski, Jacek, Tibshirani, Robert J., Williamson, Karin M., Smith, Graham, Gnanendran, Kandiah P., Bignell, S. J., Jones, S., Sleigh, J., Arnell, M., Schultz, Jan-Ake I., Fear, David W., Ganapathy, S., Moote, C., Wassermann, R., Watson, J., Armstrong, K., Calikyan, Aznif Ozsolak, Yilmaz, Oya, Kose, Yildiz, Peng, Philip, Chan, Vincent, Chung, Frances, Claxton, Andrew R., Krishnathas, Ananthan, Mezei, Gabor, Badner, Neal H., Paul, Terri L., Doyle, Jacqueline A., Mehta, Mahesh, DeLima, Luiz G. R., Silva, Lucia E. O., May, Warren L., Maliakkal, Roy J., Mehta, Mahesh, Kolesar, Richard, Arellano, Ramiro, Rafuse, Sara, Fletcher, Mary, Dunn, Geoffrey, Curran, Michael, Bragg, Paul, Chamberlain, Wayne, Crossan, MaryLou, Ganapathy, S., Sandhu, H., Spadafora, S., Mian, R., Evans, B., Hurst, L., and Katsiris, S.

Published
1997
Full Text
View/download PDF

26. The timing of the human circadian clock is accurately represented by the core body temperature rhythm following phase shifts to a three-cycle light stimulus near the critical zone

Author

Jewett, M. E, Duffy, J. F, and Czeisler, C. A

Subjects
Life Sciences (General)
Abstract

A double-stimulus experiment was conducted to evaluate the phase of the underlying circadian clock following light-induced phase shifts of the human circadian system. Circadian phase was assayed by constant routine from the rhythm in core body temperature before and after a three-cycle bright-light stimulus applied near the estimated minimum of the core body temperature rhythm. An identical, consecutive three-cycle light stimulus was then applied, and phase was reassessed. Phase shifts to these consecutive stimuli were no different from those obtained in a previous study following light stimuli applied under steady-state conditions over a range of circadian phases similar to those at which the consecutive stimuli were applied. These data suggest that circadian phase shifts of the core body temperature rhythm in response to a three-cycle stimulus occur within 24 h following the end of the 3-day light stimulus and that this poststimulus temperature rhythm accurately reflects the timing of the underlying circadian clock.

Published
2000
Full Text
View/download PDF

28. Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting

Author

Nazha, S., primary, Tanguay, S., additional, Kapoor, A., additional, Jewett, M., additional, Kollmannsberger, C., additional, Wood, L., additional, Bjarnason, G., additional, Heng, D., additional, Soulières, D., additional, Reaume, N., additional, Basappa, N., additional, Lévesque, E., additional, and Dragomir, A., additional

Published
2018
Full Text
View/download PDF

29. The Prostate Cancer Rehabilitation Clinic: A Biopsychosocial Clinic for Sexual Dysfunction after Radical Prostatectomy

Author

Matthew, A., primary, Lutzky-Cohen, N., additional, Jamnicky, L., additional, Currie, K., additional, Gentile, A., additional, Mina, D. Santa, additional, Fleshner, N., additional, Finelli, A., additional, Hamilton, R., additional, Kulkarni, G., additional, Jewett, M., additional, Zlotta, A., additional, Trachtenberg, J., additional, Yang, Z., additional, and Elterman, D., additional

Published
2018
Full Text
View/download PDF

30. Dose-response relationship between sleep duration and human psychomotor vigilance and subjective alertness

Author

Jewett, M. E, Dijk, D. J, Kronauer, R. E, and Dinges, D. F

Subjects
Behavioral Sciences
Abstract

Although it has been well documented that sleep is required for human performance and alertness to recover from low levels after prolonged periods of wakefulness, it remains unclear whether they increase in a linear or asymptotic manner during sleep. It has been postulated that there is a relation between the rate of improvement in neurobehavioral functioning and rate of decline of slow-wave sleep and/or slow-wave activity (SWS/SWA) during sleep, but this has not been verified. Thus, a cross-study comparison was conducted in which dose-response curves (DRCs) were constructed for Stanford Sleepiness Scale (SSS) and Psychomotor Vigilance Task (PVT) tests taken at 1000 hours by subjects who had been allowed to sleep 0 hours, 2 hours, 5 hours or 8 hours the previous night. We found that the DRCs to each PVT metric improved in a saturating exponential manner, with recovery rates that were similar [time constant (T) approximately 2.14 hours] for all the metrics. This recovery rate was slightly faster than, though not statistically significantly different from, the reported rate of SWS/SWA decline (T approximately 2.7 hours). The DRC to the SSS improved much more slowly than psychomotor vigilance, so that it could be fit equally well by a linear function (slope = -0.26) or a saturating exponential function (T = 9.09 hours). We conclude that although SWS/SWA, subjective alertness, and a wide variety of psychomotor vigilance metrics may all change asymptotically during sleep, it remains to be determined whether the underlying physiologic processes governing their expression are different.

Published
1999

31. Time course of sleep inertia dissipation in human performance and alertness

Author

Jewett, M. E, Wyatt, J. K, Ritz-De Cecco, A, Khalsa, S. B, Dijk, D. J, and Czeisler, C. A

Subjects
Behavioral Sciences
Abstract

Alertness and performance on a wide variety of tasks are impaired immediately upon waking from sleep due to sleep inertia, which has been found to dissipate in an asymptotic manner following waketime. It has been suggested that behavioural or environmental factors, as well as sleep stage at awakening, may affect the severity of sleep inertia. In order to determine the time course of sleep inertia dissipation under normal entrained conditions, subjective alertness and cognitive throughput were measured during the first 4 h after habitual waketime from a full 8-h sleep episode on 3 consecutive days. We investigated whether this time course was affected by either sleep stage at awakening or behavioural/environmental factors. Sleep inertia dissipated in an asymptotic manner and took 2-4 h to near the asymptote. Saturating exponential functions fitted the sleep inertia data well, with time constants of 0.67 h for subjective alertness and 1.17 h for cognitive performance. Most awakenings occurred out of stage rapid eye movement (REM), 2 or 1 sleep, and no effect of sleep stage at awakening on either the severity of sleep inertia or the time course of its dissipation could be detected. Subjective alertness and cognitive throughput were significantly impaired upon awakening regardless of whether subjects got out of bed, ate breakfast, showered and were exposed to ordinary indoor room light (approximately 150 lux) or whether subjects participated in a constant routine (CR) protocol in which they remained in bed, ate small hourly snacks and were exposed to very dim light (10-15 lux). These findings allow for the refinement of models of alertness and performance, and have important implications for the scheduling of work immediately upon awakening in many occupational settings.

Published
1999
Full Text
View/download PDF

33. Refinement of a limit cycle oscillator model of the effects of light on the human circadian pacemaker

Author

Jewett, M. E, Kronauer, R. E, and Brown, E. N

Subjects
Life Sciences (General)
Abstract

In 1990, Kronauer proposed a mathematical model of the effects of light on the human circadian pacemaker. Although this model predicted many general features of the response of the human circadian pacemaker to light exposure, additional data now available enable us to refine the original model. We first refined the original model by incorporating the results of a dose response curve to light into the model's predicted relationship between light intensity and the strength of the drive onto the pacemaker. Data from three bright light phase resetting experiments were then used to refine the amplitude recovery characteristics of the model. Finally, the model was tested and further refined using data from an extensive phase resetting experiment in which a 3-cycle bright light stimulus was presented against a background of dim light. In order to describe the results of the four resetting experiments, the following major refinements to the original model were necessary: (i) the relationship between light intensity (I) and drive onto the pacemaker was reduced from I1/3 to I0.23 for light levels between 150 and 10,000 lux; (ii) the van der Pol oscillator from the original model was replaced with a higher-order limit cycle oscillator so that amplitude recovery is slower near the singularity and faster near the limit cycle; (iii) a direct effect of light on circadian period (tau x) was incorporated into the model such that as I increases, tau x decreases, which is in accordance with "Aschoff's rule". This refined model generates the following testable predictions: it should be difficult to enhance normal circadian amplitude via bright light; near the critical point of a type 0 phase response curve (PRC) the slope should be steeper than it is in a type 1 PRC; and circadian period measured during forced desynchrony should be directly affected by ambient light intensity.

Published
1998
Full Text
View/download PDF

35. Human circadian pacemaker is sensitive to light throughout subjective day without evidence of transients

Author

Jewett, M. E, Rimmer, D. W, Duffy, J. F, Klerman, E. B, Kronauer, R. E, and Czeisler, C. A

Subjects
Life Sciences (General)
Abstract

Fifty-six resetting trials were conducted across the subjective day in 43 young men using a three-cycle bright-light (approximately 10,000 lx). The phase-response curve (PRC) to these trials was assessed for the presence of a "dead zone" of photic insensitivity and was compared with another three-cycle PRC that had used a background of approximately 150 lx. To assess possible transients after the light stimulus, the trials were divided into 43 steady-state trials, which occurred after several baseline days, and 13 consecutive trials, which occurred immediately after a previous resetting trial. We found that 1) bright light induces phase shifts throughout subjective day with no apparent dead zone; 2) there is no evidence of transients in constant routine assessments of the fitted temperature minimum 1-2 days after completion of the resetting stimulus; and 3) the timing of background room light modulates the resetting response to bright light. These data indicate that the human circadian pacemaker is sensitive to light at virtually all circadian phases, implying that the entire 24-h pattern of light exposure contributes to entrainment.

Published
1997

36. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

Author

Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K-P., Fizazi, K., Fossa, S., Germa-Lluch, J. R., Giannatempo, P., Gietema, J. A., Gillessen, S., Haugnes, H. S., Heidenreich, A., Hemminki, K., Huddart, R., Jewett, M. A. S., Joly, F., Lauritsen, J., Lorch, A., Necchi, A., Nicolai, N., Oing, C., Oldenburg, J., Ondrus, D., Papachristofilou, A., Powles, T., Sohaib, A., Stahl, O., Tandstad, T., Toner, G., Horwich, A., Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K-P., Fizazi, K., Fossa, S., Germa-Lluch, J. R., Giannatempo, P., Gietema, J. A., Gillessen, S., Haugnes, H. S., Heidenreich, A., Hemminki, K., Huddart, R., Jewett, M. A. S., Joly, F., Lauritsen, J., Lorch, A., Necchi, A., Nicolai, N., Oing, C., Oldenburg, J., Ondrus, D., Papachristofilou, A., Powles, T., Sohaib, A., Stahl, O., Tandstad, T., Toner, G., and Horwich, A.

Abstract

The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3-5 November 2016 in Paris, France. The conference included a multidisciplinary panel of 36 leading experts in the diagnosis and treatment of testicular cancer (34 panel members attended the conference; an additional two panel members [CB and K-PD] participated in all preparatory work and subsequent manuscript development). The aim of the conference was to develop detailed recommendations on topics relating to testicular cancer that are not covered in detail in the current ESMO Clinical Practice Guidelines (CPGs) and where the available level of evidence is insufficient. The main topics identified for discussion related to: (1) diagnostic work-up and patient assessment; (2) stage I disease; (3) stage II-III disease; (4) post-chemotherapy surgery, salvage chemotherapy, salvage and desperation surgery and special topics; and (5) survivorship and follow-up schemes. The experts addressed questions relating to one of the five topics within five working groups. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel. A consensus vote was obtained following whole-panel discussions, and the consensus recommendations were then further developed in post-meeting discussions in written form. This manuscript presents the results of the expert panel discussions, including the consensus recommendations and a summary of evidence supporting each recommendation. All participants approved the final manuscript.

Published
2018

37. ESMO Consensus Conference on testicular germ cell cancer:diagnosis, treatment and follow-up

Author

Honecker, F, Aparicio, J, Berney, D, Beyer, J, Bokemeyer, C, Cathomas, R, Clarke, N, Cohn-Cedermark, G, Daugaard, G, Dieckmann, K-P, Fizazi, K, Fosså, S, Germa-Lluch, J R, Giannatempo, P, Gietema, J A, Gillessen, S, Haugnes, H S, Heidenreich, A, Hemminki, K, Huddart, R, Jewett, M A S, Joly, F, Lauritsen, J, Lorch, A, Necchi, A, Nicolai, N, Oing, C, Oldenburg, J, Ondruš, D, Papachristofilou, A, Powles, T, Sohaib, A, Ståhl, O, Tandstad, T, Toner, G, Horwich, A, Honecker, F, Aparicio, J, Berney, D, Beyer, J, Bokemeyer, C, Cathomas, R, Clarke, N, Cohn-Cedermark, G, Daugaard, G, Dieckmann, K-P, Fizazi, K, Fosså, S, Germa-Lluch, J R, Giannatempo, P, Gietema, J A, Gillessen, S, Haugnes, H S, Heidenreich, A, Hemminki, K, Huddart, R, Jewett, M A S, Joly, F, Lauritsen, J, Lorch, A, Necchi, A, Nicolai, N, Oing, C, Oldenburg, J, Ondruš, D, Papachristofilou, A, Powles, T, Sohaib, A, Ståhl, O, Tandstad, T, Toner, G, and Horwich, A

Abstract

The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3-5 November 2016 in Paris, France. The conference included a multidisciplinary panel of 36 leading experts in the diagnosis and treatment of testicular cancer (34 panel members attended the conference; an additional two panel members [CB and K-PD] participated in all preparatory work and subsequent manuscript development). The aim of the conference was to develop detailed recommendations on topics relating to testicular cancer that are not covered in detail in the current ESMO Clinical Practice Guidelines (CPGs) and where the available level of evidence is insufficient. The main topics identified for discussion related to: (1) diagnostic work-up and patient assessment; (2) stage I disease; (3) stage II-III disease; (4) post-chemotherapy surgery, salvage chemotherapy, salvage and desperation surgery and special topics; and (5) survivorship and follow-up schemes. The experts addressed questions relating to one of the five topics within five working groups. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel. A consensus vote was obtained following whole-panel discussions, and the consensus recommendations were then further developed in post-meeting discussions in written form. This manuscript presents the results of the expert panel discussions, including the consensus recommendations and a summary of evidence supporting each recommendation. All participants approved the final manuscript.

Published
2018

39. Surgical safety of immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. Data from the EORTC randomized trial 30073 SURTIME

Author

Bex, A., primary, Mulders, P., additional, Jewett, M., additional, Wagstaff, J., additional, Van Velthoven, R., additional, Laguna, P., additional, Wood, L., additional, Van Melick, H., additional, Soetekouw, P., additional, Lattouf, J., additional, Powles, T., additional, De Jong, I., additional, Rottey, S., additional, Tombal, B., additional, Marreaud, S., additional, Collette, S., additional, Collette, L., additional, and Haanen, J., additional

Published
2018
Full Text
View/download PDF

42. Growth of Human Tumors in Immune-Deficient scid Mice and nude Mice

Author

Phillips, R. A., Jewett, M. A. S., Gallie, B. L., Compans, R. W., editor, Cooper, M., editor, Koprowski, H., editor, McConnell, I., editor, Melchers, F., editor, Nussenzweig, V., editor, Oldstone, M., editor, Olsnes, S., editor, Saedler, H., editor, Vogt, P. K., editor, Wagner, H., editor, Wilson, I., editor, Bosma, Melvin J., editor, Phillips, Robert A., editor, and Schuler, Walter, editor

Published
1989
Full Text
View/download PDF

43. FOREIGN

Author

Smith, Nicholas, Burgess, D. M., Reque, Lars S., Jewett, M. A., Zavitziano, Spiridion C., and Wyman, Walter

Published
1894

44. FOREIGN

Author

Daker, Goree, Rosenau, M. J., Banks, Chas. E., Burgess, D. W., Martin, Wm., Nahmens, L. S., Houghton, E. R., de Sallier Dupin, H., Williams, L. L., Woodward, R. M., JUDD, Young, G. B., Wyman, Brown, B. W., Olliphant, S. B., Hornstedt, N. W., Zavitziano, Spiridion C., Jewett, M. A., and Wyman, Walter

Published
1893

46. Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward

Author

Harshman, L.C., primary, Drake, C.G., additional, Haas, N.B., additional, Manola, J., additional, Puligandla, M., additional, Signoretti, S., additional, Cella, D., additional, Gupta, R.T., additional, Bhatt, R., additional, Van Allen, E., additional, Lara, P., additional, Choueiri, T.K., additional, Kapoor, A., additional, Heng, D.Y.C., additional, Shuch, B., additional, Jewett, M., additional, George, D., additional, Michaelson, D., additional, Carducci, M.A., additional, McDermott, D., additional, and Allaf, M., additional

Published
2017
Full Text
View/download PDF

47. A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic

Author

Kulkarni, G., primary, Hermanns, T., additional, Wei, Y., additional, Bhindi, B., additional, Satkunasivam, R., additional, Athanasopoulos, P., additional, Bostrom, P., additional, Kuk, C., additional, Li, K., additional, Templeton, A., additional, Sridhar, S., additional, Van Der Kwast, T., additional, Chung, P., additional, Bristow, R., additional, Milosevic, M., additional, Warde, P., additional, Fleshner, N., additional, Jewett, M., additional, Bashir, S., additional, and Zlotta, A., additional

Published
2017
Full Text
View/download PDF

48. Metric sub-stage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer

Author

Fransen Van De Putte, E., primary, Van Der Kwast, T., additional, Bertz, S., additional, Denzinger, S., additional, Manach, Q., additional, Compérat, E., additional, Boormans, J., additional, Jewett, M., additional, Stoehr, R., additional, Zlotta, A., additional, Hendricksen, K., additional, Rouprêt, M., additional, Otto, W., additional, Burger, M., additional, Hartmann, A., additional, and Van Rhijn, B., additional

Published
2017
Full Text
View/download PDF

50. MiR-210 is a prognostic marker in clear cell renal cell carcinoma

Author

Samaan, S. Khella, H.W.Z. Girgis, A. Scorilas, A. Lianidou, E. Gabril, M. Krylov, S.N. Jewett, M. Bjarnason, G.A. El-Said, H. Yousef, G.M.

Abstract

Accurate assessment of prognosis of clear cell renal cell carcinoma (ccRCC) is key in optimizing management plans to fit individual patient needs. miRNAs are short noncoding single-stranded RNAs that control the expression of target genes and may act as cancer biomarkers. We analyzed the expression of miR-210 in 276 cases of primary ccRCC and compared its expression in 40 pairs of adjacent normal and cancerous tissues. We assessed its expression in primary and metastatic tumors, in the common RCC subtypes, and the benign oncocytoma. The results were validated with an independent data set from The Cancer Genome Atlas. miR-210 was significantly overexpressed in ccRCC compared with normal kidney. miR-210+ patients had a statistically higher chance of disease recurrence [hazard ratio (HR), 1.82; P = 0.018] and shorter overall survival (HR, 2.46; P = 0.014). In multivariate analysis, miR-210 lost its statistically significant association with shorter disease-free survival and overall survival after adjusting for tumor size and tumor, node, metastasis stage. Papillary RCC showed comparable miR-210 overexpression, whereas decreased up-regulation was seen in chromophobe RCC and oncocytoma. A number of predicted targets that might be involved in carcinogenesis and aggressive tumor behavior were identified. miR-210 is a potential therapeutic target and independent marker of poor prognosis of ccRCC. © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results